Amgen Inc. $AMGN Shares Sold by Strs Ohio

Strs Ohio trimmed its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 8.5% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 138,887 shares of the medical research company’s stock after selling 12,909 shares during the period. Strs Ohio’s holdings in Amgen were worth $45,459,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently modified their holdings of the business. Vanguard Group Inc. raised its holdings in shares of Amgen by 1.8% during the fourth quarter. Vanguard Group Inc. now owns 54,838,826 shares of the medical research company’s stock worth $17,949,296,000 after purchasing an additional 961,975 shares during the period. Capital International Investors grew its position in shares of Amgen by 1.5% during the third quarter. Capital International Investors now owns 19,192,995 shares of the medical research company’s stock worth $5,414,296,000 after acquiring an additional 282,219 shares during the last quarter. Capital World Investors grew its position in shares of Amgen by 11.5% during the third quarter. Capital World Investors now owns 18,795,474 shares of the medical research company’s stock worth $5,303,578,000 after acquiring an additional 1,935,876 shares during the last quarter. Capital Research Global Investors grew its position in shares of Amgen by 2.7% during the third quarter. Capital Research Global Investors now owns 4,731,290 shares of the medical research company’s stock worth $1,335,168,000 after acquiring an additional 122,631 shares during the last quarter. Finally, Invesco Ltd. grew its position in shares of Amgen by 6.6% during the third quarter. Invesco Ltd. now owns 4,467,287 shares of the medical research company’s stock worth $1,260,668,000 after acquiring an additional 277,031 shares during the last quarter. 76.50% of the stock is owned by institutional investors and hedge funds.

Key Stories Impacting Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Q1 results beat expectations — AMGN reported $5.15 EPS vs. $4.73 consensus and product sales rose ~4%, with 16 drugs delivering double‑digit growth, supporting the company’s growth story. Amgen’s Q1 Earnings Top Estimates
• Positive Sentiment: Bullish analyst action — Goldman Sachs reiterated a Buy and lifted its price target to $425, signaling long‑term upside from execution and pipeline momentum. Goldman Sachs Raises PT to $425
• Positive Sentiment: Other supportive analyst notes — Some firms (e.g., William Blair) reiterated Buy ratings after the quarter, highlighting confidence in the MariTide/weight‑loss program and execution. Analyst Reiterates Buy
• Neutral Sentiment: Guidance set but roughly in line — Amgen updated FY‑2026 EPS guidance to $21.70–$23.10 (consensus ~22.29), which many read as broadly in‑line rather than materially bullish. Amgen FY2026 Guidance (press release/slide)
• Neutral Sentiment: Small, mixed analyst target moves — Truist nudged its target to $327 with a Hold rating (minimal change), leaving some investors watching for clearer directional signals. Truist Raises PT to $327
• Negative Sentiment: FDA action risk — The FDA proposed withdrawing Tavneos approval after alleging clinical‑trial data issues, raising regulatory, compliance and reputational concerns that can pressure the stock. FDA Tavneos Proposal Coverage
• Negative Sentiment: Investor apprehension over strategy/timing — Some market commentary framed the quarter as “generally in‑line” and expressed concern about Amgen’s aggressive push into obesity (MariTide) and the near‑term profit impact, contributing to selling pressure. Investor Reaction to MariTide Expansion

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the stock. Daiwa Securities Group upped their price target on shares of Amgen from $370.00 to $410.00 and gave the stock an “outperform” rating in a research report on Tuesday, February 10th. Leerink Partners restated a “market perform” rating and set a $355.00 price target on shares of Amgen in a research report on Thursday, March 5th. Deutsche Bank Aktiengesellschaft upped their price target on shares of Amgen from $285.00 to $295.00 and gave the stock a “hold” rating in a research report on Thursday, February 5th. Rothschild & Co Redburn upped their price target on shares of Amgen from $180.00 to $200.00 and gave the stock a “sell” rating in a research report on Wednesday, February 18th. Finally, Jefferies Financial Group assumed coverage on shares of Amgen in a research report on Tuesday, March 10th. They set a “hold” rating and a $350.00 price target for the company. One analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, fourteen have issued a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $357.54.

Amgen Stock Performance

Shares of AMGN opened at $329.82 on Friday. The firm has a 50-day moving average price of $358.07 and a 200 day moving average price of $340.45. The firm has a market capitalization of $178.00 billion, a PE ratio of 23.18, a P/E/G ratio of 3.42 and a beta of 0.47. The company has a quick ratio of 0.90, a current ratio of 1.14 and a debt-to-equity ratio of 5.78. Amgen Inc. has a 52-week low of $261.43 and a 52-week high of $391.29.

Amgen (NASDAQ:AMGN) last announced its earnings results on Thursday, April 30th. The medical research company reported $5.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.77 by $0.38. The firm had revenue of $8.62 billion during the quarter, compared to analyst estimates of $8.58 billion. Amgen had a net margin of 20.96% and a return on equity of 139.90%. Amgen’s revenue was up 5.8% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $4.90 EPS. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. On average, sell-side analysts anticipate that Amgen Inc. will post 22.16 earnings per share for the current fiscal year.

Amgen Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, June 5th. Investors of record on Friday, May 15th will be given a $2.52 dividend. This represents a $10.08 dividend on an annualized basis and a yield of 3.1%. The ex-dividend date is Friday, May 15th. Amgen’s dividend payout ratio is currently 70.84%.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.